Biotech Values

[DewDiligence]

Re: Antisoma NVS OXGN

>Novartis’ development plans for AS1404 include a phase III study in squamous non-small cell lung cancer, expected to start early in 2008…<

The significance of the squamous type of NSCLC being that Avastin is not indicated there, leaving a large unmet need.

> OXGN CA4P, oxgn's vascular disrupting agent (VDA) is at least as good (probably better) as Antisomas DMXXA and they will soon start a phase 3 study in ATC.<

However, ATC is an orphan indication that is much smaller than squamous NSCLC.

>[OXGN] will soon release phase 1 data from oxgn's second generation VDA, OXI4503<

It’s about time! This milestone has been in the works for about three years, IIRC.

OXGN has its 1Q07 CC next Wednesday. I’ll probably listen. Regards, Dew